Evofem Biosciences (EVFM)
(Delayed Data from OTC)
$0.02 USD
0.00 (0.00%)
Updated Apr 17, 2024 02:34 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Evofem Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 18 | 17 | 8 | 0 | 0 |
Cost Of Goods | 7 | 4 | 4 | 0 | 0 |
Gross Profit | 12 | 12 | 4 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 30 | 97 | 171 | 104 | 53 |
Income After Depreciation & Amortization | -18 | -84 | -167 | -104 | -53 |
Non-Operating Income | 71 | 7 | -38 | -39 | -27 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | 53 | -77 | -205 | -142 | -80 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 53 | -77 | -205 | -142 | -80 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 53 | -77 | -205 | -142 | -80 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -17 | -83 | -166 | -103 | -52 |
Depreciation & Amortization (Cash Flow) | 0 | 1 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -18 | -84 | -167 | -104 | -53 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 984.04 | 0.47 | 0.07 | 0.04 | 0.02 |
Diluted EPS Before Non-Recurring Items | 0.05 | -167.50 | -2,604.95 | -2,923.54 | -2,455.02 |
Diluted Net EPS (GAAP) | 0.05 | -167.50 | -2,961.02 | -3,973.01 | -3,729.39 |
Fiscal Year end for Evofem Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 4.84 | 5.11 | 2.46 | 5.81 |
Cost Of Goods | NA | 0.95 | 1.89 | 2.29 | 1.38 |
Gross Profit | NA | 3.89 | 3.22 | 0.17 | 4.43 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 7.26 | 6.77 | 7.50 | 8.01 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -3.37 | -3.55 | -7.33 | -3.58 |
Non-Operating Income | NA | 1.27 | 69.57 | -1.22 | 1.23 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -2.11 | 66.02 | -8.56 | -2.35 |
Income Taxes | NA | 0.01 | 0.01 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -2.12 | 66.01 | -8.56 | -2.35 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -2.11 | 66.01 | -8.56 | -2.35 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 11.66 | 729.98 | 1.58 | 1.27 |
Diluted EPS Before Non-Recurring Items | NA | -0.44 | 0.10 | -5.43 | -1.85 |
Diluted Net EPS (GAAP) | NA | 7.23 | 0.10 | -5.43 | -1.85 |